its derivatives (Elion, 1967 (Elion, , 1968 . This minor pathway of metabolism is important since these particular metabolites are considered to be primarily responsible for the action of these antimetabolite drugs (Elion, 1967a (Elion, , 1967b (Elion, , 1969 . Most of the drug is, however, metabolized via a catabolic pathway resulting in the formation of a variety of inactive end-products which appear in the urine within hours of administration (Elion, 1967a and b) . Concentrations of total drug in the blood rarely exceed 1 ,ug/ml and at that level currently employed methods have not been sufficiently sensitive to determine accurately the distribution of metabolized and unchanged drug (Elion, 1967b) . Recently this problem has been approached by using the rosette inhibition test to assess the level of circulating biologically active drug after the administration of antimetabolite drugs such as azathioprine (Bach, Dardenne, and Fournier, 1969a) .
The mechanism of spontaneous rosette formation is uncertain. It is postulated by Bach that antigenic sites on the red cell membranes adhere to antibodies on the cell membranes of the lymphocytes involved in antibody production (Bach et al, 1969;  907 Gregory Whelan and Sheila Sherlock Bach and Dormont, 1971) . These authors also suggest that the rosette-forming cell is thymusdependent and antigen-sensitive (Bach and Dormont, 1971) . Antilymphocyte globulin is felt to coat lymphocytes and thus prevent adherence of red cells.
Whether the immunosuppressive drugs act similarly is uncertain. However the action is not due to direct cytotoxicity as the effect is reversible at 37°C upon washing the lymphocytes involved (Bach, 1970) . Although the mechanism involved in the rosette inhibition test may be obscure, it is regarded as a good index of immunosuppressive potency. This has been best shown with antilymphocyte globulin (ALG) where survival graphs and rosette inhibition titres in animals show a good correlation (Bach, Dormont, Dandenne, and Balner, 1969) . Since the liver contains enzyme systems involved in the anabolic (eg, hypoxanthine-guanine phosphoribosyl transferase) as well as the degenerative pathway, eg, xanthine oxidase (Elion, 1967) , it seemed reasonable to postulate that the presence of significant liver disease could result in alterations to the metabolism of azathioprine. Therefore, the metabolism of azathioprine has been studied in patients with chronic liver disease, utilizing the rosette inhibition test to measure the serum immunosuppressive activity of the drug.
Patient Population
The 16 patients with active chronic hepatitis (10 patients) or primary biliary cirrhosis (six patients) were commencing therapy with azathioprine. One patient (no. 16) was taking diuretics and two patients (nos. 6 and 16) had taken, within the previous three weeks, drugs known to be associated with the enhancement of drug-metabolizing enzymes. Renal function, as assessed by urine analysis, estimation of blood urea, serum creatinine, and creatinine clearance was always normal, although this subsequently deteriorated in two patients (nos. 9 and 16).
PATIENTS WITH ACTIVE CHRONIC HEPATITIS
The ages of the 10 patients with active chronic hepatitis ranged from 12 to 50 years. Symptoms had commenced nine months to 11 years previously. Liver biopsy in all showed chronic aggressive hepatitis with or without cirrhosis. All but three patients (nos. 2, 7, and 10) had previously received ACTH or corticosteroids but none was presently taking these drugs. An attempt has been made to assess objectively overall hepatic function in each patient. Since no good absolute criteria are available, the three clinicians who were responsible for the follow-up care of these patients were asked to grade overall hepatic function on the basis of clinical features and biochemical findings without knowledge of the results of the rosette inhibition test. The criteria adopted to define good, fair, and bad hepatic function are shown in Table II . Liver biopsies werenot used inthe assessment because of thevariable size of specimens and the risk of sampling error (Scheuer, 1968) . Gamma globulin levels were elevated in all but one patient (no. 6). Smooth muscle antibody was positive in seven of 10 patients (nos. 1, 2, 4, 5, 8, 9, 10) , antinuclear factor positive in five (nos. 2, 5, 8, 9, 10) , and antimitochondrial antibody and the LE cell phenomenon positive in one each (no. 3 and no. 5 respectively). These criteria of disturbed immunity were not used in the assessment of hepatic function since they do not necessarily reflect the activity of the liver disease. Australia antigen was not detected in the serum of any patient.
PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
The six patients with primary biliary cirrhosis were diagnosed by the history, clinical features, and the results of investigations shown in Table III . Their ages ranged from 35 to 65 years and apart from one patient who was asymptomatic (no. 12) they had had symptoms for one to eight years. None were taking cholestyramine at the time of the study. These patients cannot readily be divided into several groups with regard to their hepatic function. However, since deep jaundice, ascites, and hypoalbuminaemia are considered poor prognostic signs, it can be seen that three patients (nos. 14, 15, and 16) had advanced liver disease, whereas hepatic function was better preserved in the other three patients (nos. 11, 12, and 13 Immunosuppressive activity in patients with active chronic hepatitis andprimary biliary cirrhosis Procedure Peripheral venous blood samples were taken on at least one occasion before commencing therapy and then at frequent intervals over the first 24 hours following the initial oral single dose of azathioprine (1.5 mg/kg body weight). Some patients were restudied one week after beginning therapy and again after at least two months of continuous daily medication. Observations were also made in a group of nine normal volunteer subjects consisting of male and female students, medical and laboratory personnel, ranging in age from 17 to 50 years, after a single oral dose of azathioprine (1.5 mg/kg).
Selected patients and some corresponding age-and sex-matched controls were restudied after a single oral dose of azathioprine 3.0 mg/kg body weight.
PREPARATION OF SAMPLES
Naturally occurring anti-sheep haemagglutinating antibodies were removed from the serum, initially by absorbing each serum sample a total of five times with half its volume of sheep red cells, previously washed thrice in saline, at 37°C for 30 minutes. Recently it was found that removal of these antibodies could be achieved with a similar degree of efficiency in an ultrafiltration apparatus using an XM-50 Amicon dialysing membrane (Bach, J. F., personal communication), and this procedure was adopted. All serum samples were coded and stored at -20°C until tested.
MEASUREMENT OF IMMUNOSUPPRESSIVE ACTIVITY OF AZATHIOPRINE IN SERUM
The immunosuppressive activity of each serum sample was determined utilizing the rosette inhibition test of Bach and Antoine (Bach et al, 1969a (Bach et al, 1969a) .
All serum samples were tested under code and therefore without knowledge of the patient's clinical state and liver function tests. C 57 black mice were used as a source of spleen cells. Disposable plastic tubes and pipettes were used to minimize the problems from inadequately cleaned glassware. In performing the test serial dilutions of serum in Hanks BSS (calcium-free) from 1/2 to 1/256 were made and coded to minimize subjective observer error during subsequent counting. Of all dilutions, 0.1 ml was then incubated with 0.6 ml of the spleen cells preparation containing 6 x 106 spleen cells in Hanks BSS for 90 minutes at 37°C in a water bath. Two additional tubes containing only Hanks BSS without serum served as controls. Rosette formation was then achieved by the addition of 0-25 ml of 1 % sheep red cells in saline and centrifugation of each tube for five min at 150 g at 4°C. Cells were then re-suspended by gentle to and fro rotation of the tubes. Since any delay in counting at this stage results in a decline in the number ofrosettes observed, 0-4 ml of 4 % formaldehyde in saline was then added to each tube after the resuspension process was completed (preliminary testing had previously shown that this step stabilized the rosette count for at least six hours). Cell counting was performed using a haemocytometer and the number of rosettes present per 1000 spleen cells in each tube was noted. The code was then broken and the results obtained were expressed as a percentage of control values. The titre of immunosuppressive activity of each sample was expressed as that dilution of serum which inhibited more than 25% of the rosette-forming cells. Preliminary studies in two controls showed that the peak of activity in serum was at one hour after the administration of azathioprine. In two patients no rise of immunosuppressive activity was observed after one hour and thus routinely only samples taken before treatment at one hour and at 24 hours after azathioprine were examined.
STATISTICAL ANALYSIS
The Mann Whitney test for nonparametric analytical procedures (Siegel, 1956) Thus, on initial testing, seven studies were performed in patients with only mild impairment of liver function and these patients were able to develop normal levels of serum immunosuppressive activity (P>0-1). However, the 13 patients with fair or bad hepatic function were seldom able to raise their titre of serum immunosuppressive activity and levels reached were always less than normal (p < 0001).
STUDIES AFTER PROLONGED ADMINISTRATION OF AZATHIOPRINE
Patients with active chronic hepatitis (Table II) The study was repeated in six patients after at least two months of therapy. The other four patients (nos. 3, 6, 7, and 8) were no longer available. Hepatic function had deteriorated in three patients (nos. 1, 2, and 9). One patient (no. 1) had stopped taking the drug before his deterioration. Of the three patients who had improved two now had good (Tables II, Ill , and IV). The importance of adequate hepatic function for the development of immunosuppressive activity was also seen in the patients who were studied over a prolonged period of time. As hepatic function improved or deteriorated in these patients, the titres of immunosuppressive activity in the serum rose or fell concomitantly. From the studies with azathioprine 3.0 mg/kg it can be seen that the titre of immunosuppressive activity attained in patients with adequate function was dose dependent (Table II) . However, if hepatic impairment was severe no rise in titre was achieved even with the higher dose of drug (Tables II and III) . The development of immunosuppressive activity was not related to the aetiology of the liver disease nor was it influenced by the presence or absence of serum antibodies to smooth muscle, against nuclei or mitochondria.
The mechanism of rosette inhibition activity is complex and as yet incompletely understood, thus there may be many explanations for the observed failure to develop normal immunosuppressive activity after azathioprine in patients with significant impairment of hepatic function. It seems likely that this effect could be due to alterations in the normal pattern of azathioprine metabolism by changes in absorption, activation, or degradation of the drug singly or in combination. Bach and Dardenne (1970) using S-35 labelled and intravenous azathioprine demonstrated that the abnormalities of azathioprine metabolism in patients with liver disease cannot be explained by malabsorption. Likewise, since patients with impaired hepatic function excrete in urine similar quantities of the degradative metabolites of azathioprine (mainly inorganic sulphate, thiouric acid, 6 methyl sulphinyl 8 hydroxy purine) to normal man (Elion, 1972) , it can reasonably be assumed that unaltered azathioprine does not continue to circulate in the presence of liver disease. The precise reason for the low immunosuppressive titres in liver disease remains unknown. However, this observation could well result from a change in the ratio of the activation to the degradation of the drug, possibly in the liver.
Only a small number of patients were available for restudy after several months of therapy. None of the patients with primary biliary cirrhosis had experienced any significant alteration in their liver function and therefore it was not surprising that their titres of activity had not changed. However the results in the group with active chronic hepatitis allow certain points to be made. Failure to develop immunosuppressive activity in two patients (nos. 9 and 10) was associated with lack of complete suppression of their disease processes and this might have been predicted. However, a good response in two patients (nos. 4 and 5), despite failure of their titres to rise and the lack of response in one patient (no. 2), even though he developed a normal titre when initially
